Anavex Life Sciences (NASDAQ:AVXL – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $42.00 price target on the biotechnology company’s stock. HC Wainwright’s target price points to a potential upside of 332.99% from the company’s current price.
Separately, D. Boral Capital reaffirmed a “buy” rating and set a $46.00 price target on shares of Anavex Life Sciences in a report on Tuesday.
Check Out Our Latest Stock Analysis on Anavex Life Sciences
Anavex Life Sciences Trading Down 2.1 %
Anavex Life Sciences (NASDAQ:AVXL – Get Free Report) last issued its earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. As a group, equities research analysts predict that Anavex Life Sciences will post -0.73 EPS for the current year.
Institutional Trading of Anavex Life Sciences
A number of hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. raised its stake in Anavex Life Sciences by 2.9% in the third quarter. JPMorgan Chase & Co. now owns 42,565 shares of the biotechnology company’s stock valued at $242,000 after buying an additional 1,191 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Anavex Life Sciences by 10.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,980 shares of the biotechnology company’s stock worth $193,000 after acquiring an additional 1,671 shares during the period. Foster Victor Wealth Advisors LLC grew its stake in Anavex Life Sciences by 5.6% during the 4th quarter. Foster Victor Wealth Advisors LLC now owns 37,663 shares of the biotechnology company’s stock valued at $405,000 after purchasing an additional 2,000 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Anavex Life Sciences by 8.5% in the second quarter. The Manufacturers Life Insurance Company now owns 30,510 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 2,401 shares during the period. Finally, Carnegie Investment Counsel raised its stake in shares of Anavex Life Sciences by 4.7% in the fourth quarter. Carnegie Investment Counsel now owns 76,778 shares of the biotechnology company’s stock worth $825,000 after purchasing an additional 3,445 shares during the last quarter. Hedge funds and other institutional investors own 31.55% of the company’s stock.
Anavex Life Sciences Company Profile
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
Read More
- Five stocks we like better than Anavex Life Sciences
- What Investors Need to Know About Upcoming IPOs
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- What is MarketRank™? How to Use it
- 3 Steel Stocks Soaring After Tariff Announcements
- Health Care Stocks Explained: Why You Might Want to Invest
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.